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Previous studies from acutely transfected HeLa cells have identified an acidic α-helix in the Type IIβ PtdIns5P 4-kinase (PIPkin IIβ) as a
putative novel nuclear localisation sequence (Ciruela et al. Biochem. J. 364, 587–591 2000). However, some heterogeneity in cellular localisation
was always observed, and other published aspects of PIPkin IIβ physiology are more consistent with an extra-nuclear function. As a means of
resolving whether the endogenous PIPkin IIβ is nuclear, we have used the high homologous recombination frequency of DT40 cells to knock an
epitope tag (Mosedale et al., Nat Struct Biol. 12, 763–771 2005) into one of the alleles of the DT40 PIPkin IIβ gene. We show that PIPkin IIβ is
expressed as a tagged protein, is active as revealed by immunoprecipitation and enzyme assay, and that cellular fractionation reveals that it is
indeed nuclear. Genomic tagging of endogenous proteins in DT40 cells is a technique that offers unique advantages in studying endogenous
signalling proteins.
© 2007 Elsevier Inc. Open access under CC BY license.Keywords: Phosphatidylinositol 5-phosphate; Phosphatidylinositol 5-phosphate 4-kinase; DT40 cells; Genomic tagging1. Introduction
Inositol lipids have proliferated in their number and functions
over the last twenty years such that they are now known to
participate in many cellular processes. Although most of these
functions are in the cytoplasm, there are also well defined
functions within the nucleus (for reviews see [1–5]). In particu-
lar, the function of PtdIns(4,5)P2 in the nucleus has been a major
focus of study, both in its own right as a lipid regulator of
proteins, and as a precursor for diacylglycerol to activate nuclear
PKC [1,4,5]. Thus the synthesis of PtdIns(4,5)P2 in the nucleus
has been extensively studied, but is not yet fully understood.
Radiolabelling experiments on isolated nuclei suggest that
the major route of synthesis of PtdIns(4,5)P2 is by the expected
5-phosphorylation of PtdIns4P [6]. The nuclear synthesis ofAbbreviations: Type II PIPkin, Type II Phosphatidylinositol 5-phosphate
4-kinase.
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Open access under CC BY license.   PtdIns4P from PtdIns is probably catalysed by the Type IIIβ
PtdIns 4-kinase, which has been shown to be partly nuclear in its
localisation [7,8], and then the synthesis of PtdIns(4,5)P2 must
proceed by a Type I PtdInsP kinase (PIPkin), most likely the
Type Iα [4,9] (human nomenclature— the mouse homologue is
PIPkin Iβ). However, there is also evidence in the nucleus for
the alternative route of PtdIns(4,5)P2 synthesis [10], which is the
4-phosphorylation of PtdIns5P by Type II PIPkins. For example,
PtdIns5P is found in the nucleus and its nuclear levels change
with the cell cycle [11] or when cells are stressed [12], though its
route of synthesis is currently unknown.
Of the Type II PIPkins, PIPkin IIβ has also been suggested to
be primarily nuclear, and it may be that a fraction of PIPkin IIα is
nuclear also [9,13]. We previously showed that the nuclear
localisation of acutely transfected PIPkin IIβ was absolutely
dependent on a novel nuclear localisation sequence [13] consist-
ing of an acidicα-helix 16 amino acids long, numberedα-helix 7
in the PIPkin IIβ structure described by Rao et al. [14]. We also
showed more recently that mutating a single amino acid within
that α-helix, substituting Met 296 for a Thr, caused a significant,
though not complete, shift to a cytoplasmic distribution [15]. A
line-up of Type II PIPkins shows that this α-helix is highly
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sequence has the same 296 Met–Thr subsitution), with the
exception of Zebrafish, where there is an insertion of four extra
amino acids. From our earlier work [13] we can infer that in
invertebrates (Fig. 1) and possibly in Danio, PIPkin IIβ will not
be nuclear, and in rat it will be only partly nuclear [15]. Recently,
Gozani et al. [16] have presented evidence that transfected
PIPkin IIβ can modulate PtdIns5P-mediated events in the
nucleus, and Jones et al. have implicated phosphorylation by p38
stress kinase in the regulation of nuclear PIPkin IIβ [12].
However, set against all this evidence for a nuclear localisation
and function for PIPkin IIβ is the fact that it was first cloned by its
apparent interaction with a cell surface receptor— that for TNF-α
[17]. Moreover, PIPkin IIβ has subsequently been reported to
associate with the EGF receptor [18]. The knock-out mouse for
PIPkin IIβ shows a phenotype of increased insulin sensitivity
[19], consistent with the observations fromCarricabura et al. [20],
who showed that increasing PIPkin IIβ by transfection resulted in
decreased PtdIns(3,4,5)P3 production in response to insulin,
probably caused by increased PtdIns(3,4,5)P3 degradation. The
suggested mechanism was that PtdIns5P is a stimulator of PtdInsFig. 1. Nuclear localisation sequences in Type IIβ PIPkins. A. This is a line-up of re
other species, with the human nuclear localisation sequence described by Ciruela et
B. The complete sequence of the human enzyme is shown, with the chicken sequen
database). The human nuclear localisation sequence is underlined.(3,4,5)P3 phophatase(s) [20]. All these data together suggest a
(perhaps major) cytoplasmic function for PIPkin IIβ. Finally, in
all our transfection experiments, we frequently saw some
cytoplasmic PIPkin IIβ present, even when it was mostly nuclear,
and indeed, there were also 5–10% of cells in every transfected
dish with very little in the nucleus and the majority in the
cytoplasm [13]. Moreover, differences between transfected and
endogenous localisations have also been observed with Type I
PIPkins (e.g. human Type Iβ PIPkin [21,22]).
Thus we are in a position with PIPkin IIβ, as with many
other proteins, that acute transfection may not be giving the full
picture of its physiological location and regulation — indeed
we actually have no evidence for a nuclear location of the
endogenous enzyme. One way round this problem in the ab-
sence of a highly isoform-specific antibody is to tag the
endogenous protein genetically. This can be done comparatively
easily by exploiting the extremely high rate of homologous
recombination of DT40 cells [23], as exemplified by the tagging
of Hef, a protein component of the Fanconi anemia-related
tumor-suppressor complex, by Mosedale et al. [24]. Here we
describe the generation and characterisation of a DT40 cell thatsidues 275 to 310 of human Type IIβ PIPkin and the corresponding residues of
al. [13] underlined; species with an identical localisation sequence are in bold.
ce aligned with it (note that the start of the chicken enzyme is unclear from the
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this cell line to show that PIPkin IIβ is indeed a nuclear enzyme.
2. Materials and methods
2.1. Cell culture, transfection and visualisation
DT40 cells were cultured in RPMI 1640 plus glutamine supplemented with
7% (v/v) foetal calf serum, 3% (v/v) heat-treated chicken serum, 1% (v/v)
penicillin/streptomycin solution (GIBCO) and 5 mM 2-mercaptoethanol at
37 °C, 5% CO2. Puromycin was added at a final concentration of 500 ng/ml
where appropriate. For transfection, 20×106 cells were harvested, washed and
resuspended in 600 μl of cold PBS and mixed with 30 μg of linear homologous
recombination cassette DNA (for molecular tagging of the type IIβ PIPkin) and
transferred to a chilled electroporation cuvette. Transfection was by the
Nucleofector method (Amaxa Biosystems). Cells were placed on ice for 5 min,
diluted in DT40 medium and allowed to recover for 24 h at 37 °C, 5% CO2.
Potential homologous recombinants were transferred to 96 well plates and
selected by the addition of puromycin. Resistant colonies were observed after
9 days and were cultured for further analysis. For GFP studies (acute
transfection), 10 μg of plasmid DNA was similarly transfected and cells
allowed to recover for 24 h at 37 °C, 5% CO2 in dishes containing DT40
medium and poly-D-lysine coated cover slips. After recovery, cover slips were
washed 3 times in sterile PBS and cells fixed for 45 min on ice with 0.1 M
NaH2PO4 pH 7.4 containing 4% (v/v) paraformaldehyde. Cover slips were
washed in PBS and mounted on microscope slides with 20 μl ProLong Gold
Antifade reagent (Molecular Probes). Cells expressing GFP-tagged PIPKIN
were visualised with a Zeiss Axiovert 100 M confocal microscope.
2.2. Molecular tagging of Type IIβ PIPkin
A summarised depiction of the strategy used is shown in Fig. 2. The
sequence of Gallus gallus (DT40) genomic DNA was obtained from the
ensembl genome browser (http://www.ensembl.org). To generate flanking
regions of homology required to tag the type II Beta PIPkin, primer pairs
designed to facilitate directional cloning were used to PCR amplify regions
immediately 5′ and 3′ of the type II beta PIPkin stop codon (2.2 and 3.6 kb
respectively), from DT40 genomic DNA using the LA-PCR kit (TAKARA BIO,
Japan). The 5′ arm was amplified with the forward primer: (5′-CATATC-
GATGTGTGCAGTTTGTCTCAGTCC-3′) and reverse: (5′-TACTCTA-
GATGTCAGGATATTGGACATAAATTC-3′). The 3′ arm was amplified with
forward: (5′-CATGGATCCTCATCTCCAGCCTTCAGAGG-3′) and reverse:
(5′-TACGCGGCCGCAGAGCAAGGAGAATCAGTAGTG-3′). Amplified
arms were sub cloned separately into pBluescript SK+ (Stratagene) and
confirmed by DNA sequencing. Arms were then individually sub cloned into a
pBluescript derivative containing an XbaI–FLAG–(His6)2–STOP sequence
immediately followed by a unique BamHI restriction site. A puromycin drug
resistance cassette was then cloned into the BamHI site (Fig. 2). DNA wasFig. 2. Schematic depiction of strategy for making constructs for genomic
tagging in DT40 cells. See Methods section and text for further details.prepared by endotoxin free maxi-prep (Qiagen) and linearised prior to
transfection. Integration of the tag at the correct genomic location was
confirmed by PCR analysis of genomic DNA from transfected, puromycin
resistant cells using primers internal [5′-GGAGAGTGAAGCAGAACGTGG-
3′] and external [5′-CCTCAGCTCCGACGTTGCCATG-3′] to the site of
genetic recombination.
2.3. Extraction of genomic DNA
15×106 cells were harvested, washed in sterile PBS and resuspended in
0.5 ml of (100 mM Tris–HCl pH 8.5, 5 mM EDTA pH 8.0, 0.2% SDS, 200 mM
NaCl, 100 μg/ml proteinase K). Cells were incubated at 37 °C for 4 h and
genomic DNA precipitated by addition of an equal volume of isopropanol.
Genomic DNA was pelleted by centrifugation at 13,000 rpm for 5 min and
washed once in 70% ethanol. Pellets were resuspended in 100 μl of 10 mMTris–
HCl pH 8.0 containing 60 μg of RNase A and incubated at 37 °C until dissolved.
2.4. Preparation of protein extracts
50×106 cells were harvested, washed in PBS once, and resuspended in
protein extraction buffer (1×PBS containing 5 mM EDTA pH 8.0, 1% (v/v)
triton X-100, 1 mM PMSF and 1:10 (v/v) of protease inhibitor cocktail (Sigma)).
Cells were lysed on ice water for 20 min and the lysate cleared by centrifugation
at 13,000 rpm for 5 min at 4 °C. Protein concentrations were estimated with the
detergent compatible protein assay kit (Biorad).
2.5. Fractionation of cells
DT40 WT and JPR3 cells (a clone with Type IIβ PIPkin tagged — see
Results) were grown to approximate 2.5×106 cells/ml in medium. 400 ml of
each culture was harvested and washed in PBS once. Cell pellets were
resuspended in 0.813 ml of 1× swell buffer (5 mM Tris–HCl pH 7.4 with
1.5 mM KCl and 2.5 mM MgCl2) in 50 ml tubes. Tubes were placed on ice for
exactly 10 min. 33 μl of cold 33 mM EGTA (pH7.4) was added and then cells
were syringed through a 23-gauge needle ten times. Immediately after syringing,
160 μl of sucrose solution (1.8 M sucrose prepared in lysis buffer (10 mM Tris–
HCl pH 7.4 with 1 mM EGTA, 1.5 mM KCl and 5 mM MgCl2)) followed by
2.7 μl of 1 M MgCl2 solution were added.
Samples were layered onto 4 ml of 2.3 M sucrose (prepared in lysis buffer)
and spun at 35,000 rpm for 1 h on a SW55Ti rotor using Beckman Optima L-100
XP Ultracentrifuge. After spinning, a 300 μl volume was collected from the top
of the gradient, which we took to be representative of the cytoplasmic fraction.
The nuclei (white pellet on the bottom of the centrifuge tube) were resuspended
in 1 ml of 0.32 M sucrose in lysis buffer. Nuclei were pelleted, and the absence
of contaminating whole cells was confirmed by microscope examination. They
were lysed in 75 μl of lysis buffer P1 (containing 1×PBS, 0.1% (v/v) Triton X-
100 and 0.5% protease inhibitor cocktail) on ice for 20 min. Samples of both
cytoplasmic and nuclear fractions were taken for SDS PAGE and Western
blotting (below) with anti-histone or anti-actin antibodies (to assess purity), and
the remainder was used for affinity purification of FLAG–His6 tagged proteins
using TALON beads as described below.
2.6. SDS PAGE and Western blotting
Protein samples were resolved by electrophoresis on 12.5% polyacrylamide
gels using the Protean III system (Biorad). Electrophoresed proteins were
transferred to nitrocellulose membrane using a Trans-blot transfer cell (Biorad).
Membranes were blocked in 1×PBS containing 0.1% (v/v) tween-20 and 4%
(w/v) fat free milk powder and probed with the appropriate antibodies diluted in
the same solution. Unbound antibodies were washed off with 1×PBS containing
0.1% (v/v) tween-20, and after addition of HRP-linked secondary antibodies, the
blot was incubated with Super Signal Western blot development reagent
(Pierce). Protein bands were quantified by densitometry using a GeneGnome
50000 (Syngene, MD, USA), and then visualised for Figures by exposure to
film. Antibodies used were: Anti-β-actin monoclonal antibody (AC74, Sigma);
Anti-histone H3 polyclonal antibody (ab1791, Abcam); Anti-FLAG M2
monoclonal antibody (200472, Stratagene).
Fig. 3. Localisation of human Type II PIPkins acutely transfected into DT40
cells. DT40 cells were acutely transfected with GFP-tagged Type II PIPkins, and
imaged with light microscopy (A and C) or by confocal flourescence
microscopy (B and D). A and B, Type IIα PIPkin; C and D, Type IIβ PIPkin
with a Glu300Asp mutation (see text and Fig. 2C).
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Cells were harvested, washed in PBS and lysed in protein extraction buffer
as described. Typically, 50 μl of Talon metal affinity resin (Invitrogen) was pre
washed 3 times in 1 ml of protein extraction buffer and added to 0.8 mg of whole
cell protein extract made up to a total volume of 250 μl with protein extraction
buffer. Samples were incubated on a rotating wheel for 2 h at 4 °C. Resin was
pelleted by centrifugation at 10,000 rpm and washed 3 times in wash buffer
(50 mM sodium phosphate buffer pH 7.0, 300 mM NaCl, 1% (v/v) glycerol,
1:200 (v/v) protease inhibitor cocktail) and bound proteins were eluted in 50 μl
of elution buffer (50 mM sodium phosphate buffer pH 7.0, 300 mM NaCl, 1%
(v/v) glycerol, 150 mM imidazole, 1:200 (v/v) protease inhibitor cocktail).
Eluted proteins were submitted to SDS PAGE as described above, blotted with
anti-FLAG antibodies.
2.8. Immunoprecipitation of FLAG–His6-tagged proteins
750×106 cells were harvested, washed in PBS and lysed in 2 ml of protein
extraction buffer as described. Clearing the crude lysate by centrifugation
yielded approximately 1.8 ml of protein extract, to which 3 μg of anti His6
monoclonal antibody (B D Biosciences) was added. Antibody containing
extracts were incubated on ice for 1 h with occasional mixing by inversion.
Protein G sepharose was equilibrated by washing 3 times in 1 ml of protein
extraction buffer and 50 μl added to samples which were incubated on a rotating
wheel at 4 °C for 16 h. Sepharose was pelleted by centrifugation at 2000 rpm and
washed twice in 1 ml of cold TBS and once in 1 ml of cold PBS.
Immunoprecipitated proteins were prepared for kinase activity assay by washing
the pellet in 500 μl of PIPkin reaction buffer (50 mM Tris–HCl pH 7.4, 80 mM
KCl, 10 mM Mg acetate, 2 mM EGTA).
2.9. Kinase activity assay
Immunoprecipitated proteins were resuspended in 50 μl of 10 mM Tris–HCl
pH 7.4 and 100 μl of 2× PIPkin reaction buffer and combined with substrate
(60 μM phosphatidylethanolamine, 6 μM phosphatidylinositol-5-phosphate
sonicated in 50 μl of 10 mM Tris–HCl pH 7.4 to form micelles). Kinase
reactions were initiated by the addition of 5 μCi of γ–32P–ATP (New England
Nuclear, Boston USA) and incubated at 30 °C for 2 h. Reactions were stopped
by addition of 500 μl CHCl3:CH3OH (1:1 v/v) and 125 μl 2.4 N HCl. Folch
lipids [25] (20 μl) extracted from porcine brain were added as carrier.
Phosphorylated lipids were extracted as described [11] and resolved by thin
layer chromatography on silica-coated glass plates (activated by exposure to
50% (v/v) CH3OH, 1% (w/v) potassium oxalate, 2 mM EGTA followed by
baking at 110 °C for 1 h) in a pre-equilibrated Whatman 3MM paper-lined tank.
TLC plates were developed in solvent phase (28:40:10:6 (v/v) CHCl3:CH3OH:
H2O:NH4OH) until solvent front reached to the top of the plate. Radioactive
lipids were visualised by autoradiography.
2.10. Site-directed mutagenesis
Site-directed mutagenesis was performed on the human Type IIβ PIPkin
cloned into pEGFP–C1 (Clontech) using the QuikChange mutagenesis method
(Stratagene), to introduce an Glu300Asp amino acid substitution into the human
nuclear localisation sequence producing the equivalent chicken sequence: (289-
DRAEQEEMEVE[E300D]RAEDEE-306). Mutagenesis was confirmed by
DNA sequencing.
3. Results and discussion
3.1. Localisation of acutely transfected PIPkins in DT40 cells
The chicken sequence of PIPkin IIβ is shown in Fig. 1B, and
reveals that there is an Aspartate instead of Glutamate at residue
300 in the relevant α-helical nuclear localisation sequence [11].
This is unlikely to alter the structure of the α-helix, as determinedby sequence analysis [13,26], but nevertheless we mutated that
residue in our GFP-tagged human clone to Aspartate before
comparing the localisation of the human PIPkin IIα and IIβ in
DT40 cells. As we found previously, they were respectively
predominantly cytosolic and nuclear (Fig. 3), although the degree
to which PIPkin IIβ is cytosolic is difficult to assess from these
images. However, the difference between them is very similar to
that observed in HeLa cells [11], confirming that the nuclear
transport mechanism that recognises this localisation sequence is
functional in acutely transfected DT40 cells.
3.2. Genomic tagging
Fig. 2 shows in outline the strategy used in tagging PIPkin
IIβ in DT40 cells (see Materials and Methods, and Ref. [24] for
more details). In brief, the last 2.6 kbp of the PIPkin IIβ gene,
and the following 3.6 kbp base pairs, were cloned and inserted
into a plasmid which placed a FLAG–(His6)2 double-tag,
followed by a puromycin selection cassette between them.
Transfection of this into DT40 cells followed by puromycin
selection produces cells which have the tag attached to the C-
terminus of the protein [24] when expressed by one of the two
alleles. All our experiments were conducted on one clonal line
derived from this procedure, which we called JPR3.
Successful integration of the tag at the correct genomic
location was confirmed by PCR analysis of the corresponding
genomic DNA (see Methods), and the expression of the tagged
protein was demonstrated by the experiment shown in Fig. 4. A
Nickel bead pull-down followed by blotting with an anti-FLAG
antibody revealed a single clear band (of the correct molecular
Fig. 4. Nickel bead pull-down of FLAG–(His6)2–tagged PIPkin IIβ from DT40
cells. Wild type cells (left) or PIPkin IIβ-tagged cells (JPR3) were lysed, and a
nickel bead pull-down, imadazole elution and Western blotting with anti-FLAG
antibody was performed as described in the Methods section (A). A portion of the
lysate from each cell preparationwas kept and blotted for actin to control for similar
numbers of cells used (B). The expected position of a 53 kDMWprotein (the same
as FLAG–(His6)2 tagged PIPkin IIβ) is indicated by the arrow on Fig. 4A.
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To confirm that this is tagged PIPkin IIβ and is correctly folded,
we immunoprecipitated it from the tagged cells with anti-His6
antibody and assayed for PtdIns5P 4-kinase activity, with
recombinant Human PIPkins IIα and IIβ as controls. As we
have found before, PIPkin IIβ is much less active than PIPkin
IIα under these assay conditions (Fig. 5), but nevertheless from
the ‘tagged’ cells we were able to immunoprecipitate activity
that was significantly above the background from Wild-type
cells. In three independent experiments, the ratio (‘tagged’ cells
to Wild-type) of immunoprecipitated enzyme activity, quanti-
fied by densitometry or by scintillation counting, was 2.37±
0.27 (this is different from unity with a Pb0.01 by Student's
t test).
3.3. Localisation of PIPkin IIβ
The level of expression of PIPkin IIβ was too low for
immunocytochemistry using either anti-FLAG or anti-HisFig. 5. Activity of tagged PIPkin IIβ in DT40 cells. Wild type cells (WT) or cells
with PIPkin IIβ tagged with FLAG–(His6)2 (JPR3) were lysed and split into two
portions. A. One half was immunoprecipitated with anti-FLAG antibody, and
the precipitate assayed for PtdIns5P 4-kinase activity, as described in the
Methods section. Also assayed were recombinant (human) PIPkin IIα and
PIPkin IIβ enzymes (these two at the same protein concentration). The location
of the radioactive PtdIns(4,5)P2 spot is indicated with an arrow. Spots were
quantified by densitometry or by scraping and scintillation counting. B. The
other half of each lysate was processed by a nickel bead pull-down, imidazole
elution and Western blotting with anti-FLAG, to confirm expression of Type IIβ
PIPkin. The expected position of a 53 kD MW protein (the same as FLAG–
(His6)2 tagged PIPkin IIβ) is indicated by the arrow on Fig. 5B.antibodies (we found that DT40 cells had a high background
with both sets of antibodies— significantly higher than several
mammalian cell lines in comparative experiments). However,
we could gain quantitative insight into its localisation by
fractionating DT40 cells into nuclear and cytoplasmic fractions,
blotting a portion of these with anti-actin and anti-H3 histone as
markers for the purity of the fractions, and then quantifying the
PIPkin IIβ content of the remainder by Nickel bead pull-down
followed by anti-FLAG blotting, as described above (Fig. 4).
We assessed the cytoplasmic contamination of the nuclear
fractions by blotting for β-actin. This is not a perfect marker, as
we would expect a small percentage of actin to be truly nuclear
(see [1,27]), but it served to confirm independently our
microscopical examinations, which told us that the cells had
been lysed and that we had prepared pure nuclei. The
predominance of PIPkin IIβ in the nuclear fraction demon-
strates the nuclear localisation of the endogenous enzyme. A
key question is: how much of the small amount of PIPkin IIβ in
the cytoplasmic fraction (Fig. 5B) can be accounted for by
nuclear disintegration or by leakage of PIPkin IIβ during the
fractionation? We have used a histone antibody as a marker for
this, but there is no perfect marker in this context. Histone H3
has a lower molecular weight than PIPkin IIβ, so it could be
argued to be more likely to leak out than the PIPkin; however,
Histone H3 is also integral to chromatin structure whereas
PIPkin IIβ is probably not, and so Histone H3 could be argued
to be less likely to leak out. As we do not know to what degree
PIPkin IIβ is freely diffusable in the nucleoplasm, these
arguments limit the degree to which we can unambiguously
assign a complete nuclear localisation to PIPkin IIβ, and they
also make it pointless to pursue other nuclear markers - each
will suffer from similar caveats. However, the data in Fig. 6 do
enable us to say that within the error limits of our protocol, the
endogenous PIPkin IIβ in these cells is mostly nuclear.
In conclusion, we have shown that genomic tagging of
PIPkin IIβ reinforces our earlier acute transfection studies [13].
The issue of whether there is any cytoplasmic PIPkin IIβ at all,
as some experiments imply (see Introduction), cannot beFig. 6. Nuclear and cytoplasmic fractions of DT40 cells. Wild type (WT) or cells
with PIPkin IIβ tagged with FLAG–(His6)2 (JPR3) were fractionated into
cytoplasmic and nuclear fractions as described in the Methods section. A portion
of each fraction was Western-blotted for Histone H3 or actin, and the rest was
submitted to the standard nickel bead pull-down followed by imidazole elution
and Western blotting with anti-FLAG (see Fig. 4 and Methods), to quantify the
amount of tagged PIPkin IIβ.
1314 J.P. Richardson et al. / Cellular Signalling 19 (2007) 1309–1314resolved by our data. But we can support the likely physio-
logical significance of nuclear PIPkin IIβ and PtdIns5P [11–
13,16], and importantly, our data also confirm the reality and
novelty of PIPkin IIβ's unusual nuclear localisation sequence
[13]. Finally, we suggest that this technique may be useful to
study other signalling molecules for which transfection or a lack
of good antibodies is a hindrance. As well as exploring the true
localisation of a protein (as we have done here), this approach
enables its physiological interactions with other proteins, or
changes in localisation or post-translational modifications to be
followed in a clear and unambiguous way.
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